Rodatristat ethyl

Rodatristat ethyl (KAR5585) is a first-in-class oral tryptophan hydroxylase 1 (TPH1) Inhibitor with nanomolar in vitro potency. Rodatristat ethyl reduces the level of 5-HT and significantly reduces pulmonary arterial hypertension (PAH) [1][2].

Product Specifications

CAS Number

[1673571-51-1]

Product Name Alternative

KAR5585

UNSPSC

12352005

Target

5-HT Receptor; Tryptophan Hydroxylase

Type

Reference compound

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/rodatristat-ethyl.html

Purity

98.04

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

ClC1=CC(C2=CC=CC=C2)=C([C@@H](OC3=NC(N)=NC(N4CCC5(CN[C@H](C(OCC)=O)C5)CC4)=C3)C(F)(F)F)C=C1

Molecular Formula

C29H31ClF3N5O3

Molecular Weight

590.04

References & Citations

[1]Aiello RJ, et al. Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Modelsof Pulmonary Hypertension. J Pharmacol Exp Ther. 2017 Feb;360 (2) :267-279.|[2]Alice Melão, MSc. Early Results on Rodatristat Ethyl Support Launch of Phase 2 Trial in PAH Patients. FEBRUARY 4, 2019.